MAOB and Parkinson disease: These investigations stemmed from the well-characterised capability of compounds featuring a biaryl-linked motif and a ((3-fluorobenzyl)oxy)phenyl pharmacophore, both presented within compound 6, to modulate sodium channels for the reduction in neuronal hyperexcitability (for epilepsy), and to inhibit an oxidase (monoamine oxidase B) in the brain (for Parkinson’s disease) [98,99,100,101].